Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use.

Publisher: Springer Country of Publication: United States NLM ID: 9803531 Publication Model: Print Cited Medium: Internet ISSN: 1556-3308 (Electronic) Linking ISSN: 10943412 NLM ISO Abbreviation: J Behav Health Serv Res Subsets: MEDLINE

Publication: 2006- : New York, NY : Springer
Original Publication: Northbrook, IL : Thousand Oaks, CA : Association of Behavioral Healthcare Management ; Sage Publications, c1998-

Buprenorphine/*administration & dosage ; Health Services Accessibility/*organization & administration ; Naloxone/*administration & dosage ; Opioid-Related Disorders/*drug therapy; Humans ; Interviews as Topic ; Opiate Substitution Treatment ; Program Evaluation ; Qualitative Research ; United States

Medication for opioid use disorder (MOUD) is a key strategy for addressing the opioid use disorder crisis, yet gaps in MOUD provision impede this strategy's benefits. The research reported here sought to understand what distinguishes low- and high-performing organizations in building and using capacity to provide MOUD. As part of a mixed methods MOUD implementation trial, semi-structured telephone interviews were conducted with personnel from low- and high-performing MOUD-providing organizations. Seventeen individuals from 17 organizations were interviewed. Findings demonstrate the importance of individual, organization, and community-level factors in supporting the building and use of MOUD capacity. Low- and high-performing organizations showed different patterns of facilitators and barriers during the implementation process. The key difference between low- and high-performing organizations was the level of organizational functioning. A better understanding of an organization's assets and deficits at the individual, organizational, and community levels would allow decision-makers to tailor their approaches to MOUD implementation.

Med Care. 2017 Apr;55(4):336-341. (PMID: 28296674)
Addiction. 2016 Dec;111(12):2079-2081. (PMID: 27412876)
Implement Sci. 2008 Oct 02;3:41. (PMID: 18831766)
Health Serv Res. 2003 Apr;38(2):751-76. (PMID: 12785571)
N Engl J Med. 2016 Mar 31;374(13):1232-42. (PMID: 27028913)
Health Educ Res. 2009 Apr;24(2):292-305. (PMID: 18469319)
Psychiatr Serv. 2018 Oct 1;69(10):1046-1048. (PMID: 30099944)
Psychiatr Serv. 2008 Aug;59(8):909-16. (PMID: 18678689)
J Subst Abuse Treat. 2017 Jul;78:1-7. (PMID: 28554597)
Addict Sci Clin Pract. 2015 May 28;10:14. (PMID: 26016484)
J Subst Abuse Treat. 2016 Mar;62:68-73. (PMID: 26654934)
J Addict Med. 2018 Mar/Apr;12(2):85-91. (PMID: 29176511)
Addiction. 2019 Mar;114(3):471-482. (PMID: 30194876)
Adm Policy Ment Health. 2016 Nov;43(6):991-1008. (PMID: 27439504)
Am J Addict. 2013 Nov-Dec;22(6):574-80. (PMID: 24131165)
Psychol Addict Behav. 2011 Jun;25(2):215-24. (PMID: 21480679)
Implement Sci. 2017 Nov 15;12(1):135. (PMID: 29141653)
Psychol Serv. 2009 Feb 1;6(1):74-84. (PMID: 20401336)
Obstet Gynecol Clin North Am. 2014 Jun;41(2):241-53. (PMID: 24845488)
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75. (PMID: 25747920)
Worldviews Evid Based Nurs. 2014 Aug;11(4):219-26. (PMID: 24986669)
Med Care. 2016 Oct;54(10):901-6. (PMID: 27623005)
Ann Intern Med. 2018 Aug 7;169(3):190-192. (PMID: 29913514)
N Engl J Med. 2014 May 29;370(22):2063-6. (PMID: 24758595)
J Stud Alcohol Drugs. 2014 May;75(3):476-85. (PMID: 24766760)
Am J Public Health. 2015 Aug;105(8):e55-63. (PMID: 26066931)
Addiction. 2016 Apr;111(4):695-705. (PMID: 26599131)
J Subst Abuse Treat. 2016 Jul;66:48-53. (PMID: 27211996)
Subst Abus. 2016;37(1):47-53. (PMID: 26168816)
Ann Intern Med. 2018 Aug 7;169(3):137-145. (PMID: 29913516)
JAMA. 2016 Sep 20;316(11):1211-1212. (PMID: 27654608)
J Addict Med. 2015 Sep-Oct;9(5):358-67. (PMID: 26406300)
Lancet. 2011 Apr 30;377(9776):1506-13. (PMID: 21529928)
Mol Psychiatry. 2019 Dec;24(12):1868-1883. (PMID: 29934549)
Ann Fam Med. 2014 Mar-Apr;12(2):128-33. (PMID: 24615308)
Ann Fam Med. 2017 Jul;15(4):359-362. (PMID: 28694273)
Adm Policy Ment Health. 2011 Mar;38(2):65-76. (PMID: 20957426)
Lancet. 2003 Oct 11;362(9391):1225-30. (PMID: 14568747)

R01 DA030431 United States DA NIDA NIH HHS; R01 DA041415 United States DA NIDA NIH HHS; R01 DA044159 United States DA NIDA NIH HHS; UL1 TR002373 United States TR NCATS NIH HHS

36B82AMQ7N (Naloxone)
40D3SCR4GZ (Buprenorphine)

Date Created: 20200430 Date Completed: 20210909 Latest Revision: 20240802

20240802

PMC7578054

10.1007/s11414-020-09706-4

32347426